Porta C, Riboldi E, Sica A. Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett. 2011;305:250–62.
Vatanasapt V, Uttaravichien T, Mairiang E-O, et al. Cholangiocarcinoma in north-east Thailand. Lancet. 1990;335:116–7.
Kim HG, Han J, Kim M-H, et al. Prevalence of clonorchiasis in patients with gastrointestinal disease: a Korean nationwide multicenter survey. World J Gastroenterol. 2009;15:86–94.
Mostafa MH, Sheweita SA, O’Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev. 1999;12:97–111.
Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.
Sarid R, Gao SJ. Viruses and human cancer: from detection to causality. Cancer Lett. 2011;305:218–27.
Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-part B: biological agents. Lancet Oncol. 2009;10:321–2.
Bouchard MJ, Navas-Martin S. Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett. 2011;305:123–43.
Bosch FX, Lorincz A, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.
Walboomers JMM, Jacobs MV, Manos MM, et al. Human papilloma-virus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.
Korzeniewski N, Spardy N, Duensing A, Duensing S. Genomic instability and cancer: lessons learned from human papillomaviruses. Cancer Lett. 2011;305:113–22.
Garland SM. Human papillomavirus update with a particular focus on cervical disease. Pathology. 2002;34:213–24.
Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186–91.
Shah KV. SV40 and human cancer: a review of recent data. Int J Cancer. 2007;120:215–23.
Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2005;23:2388–94.
Villa LL. HPV prophylactic vaccination: the first years and what to expect from now. Cancer Lett. 2011;305:106–12.
Ma B, Xu Y, Hung C-F, Wu T-C. HPV and therapeutic vaccines: where are we in 2010? Curr Cancer Ther Rev. 2010;6:81–103.
Trunz BB, Fine PEM, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173–80.
Zbar B, Rapp HJ. Immunotherapy of guinea pig cancer with BCG. Cancer. 1974;34:1532–40.
Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol. 1976;116:180–3.
Sylvester RJ. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol. 2011;18:113–20.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
Luo Y, Henning J, O’Donnell MA. Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol. 2011;2011:728930.
Gontero P, Bohle A, Malmstrom P-U, et al. The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer. Eur Urol. 2010;57:410–29.
Diaz JA, Griffith RA, Ng JJ, Reinert SE, Friedmann PD, Moulton AW. Patients’ use of the internet for medical information. J Gen Intern Med. 2002;17:180–5.
Betsch C, Sachse K. Dr. Jekyll or Mr. Hyde? (How) the internet influences vaccination decisions: recent evidence and tentative guidelines for online vaccine communication. Vaccine. 2012;30:3723–6.
Cantwell A. Cancer-causing vaccines, Polio, AIDS, and monkey business. http://rense.com/general54/Cancer-causing_vaccinesR.htm (2012). Accessed 27 Feb 2012.
Vaccines cause cancer: from hell to veins. http://gdsajj.wordpress.com/2010/06/27/vaccines-cause-cancer. http://orbisvitae.com/ubbthreads/ubbthreads.php?ubb=showflat&Number=53487 (2012). Accessed 27 Feb 2012.
Tanner R. Do vaccines cause cancer? Cancerous cell lines used in the development of vaccines. http://orbisvitae.com/ubbthreads/ubbthreads.php?ubb=showflat&Number=53487 (2012). Accessed 27 Feb 2012.
Goldmacher VS, Thilly WG. Formaldehyde is mutagenic for cultured human cells. Mutat Res. 1983;116:417–4122.
Ragan DL, Boreiko CJ. Initiation of C3H/10T1/2 cell transformation by formaldehyde. Cancer Lett. 1981;13:325–31.
Offit PA, Jew RK. Addressing parent’s concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics. 2003;122:1394–401.
Epidemiology of chronic occupational exposure to formaldehyde: report of the ad hoc panel on health aspects of formaldehyde. Toxicol Ind Health. 1988;4:77–90.
Til HP, Woutersen R, Feron VJ, et al. Two-year drinking-water study of formaldehyde in rats. Food Chem Toxicol. 1989;27:77–87.
van der Kuyl AC, Cornelissen M, Berkhout B. Of mice and men: on the origin of XMRV. Front Microbiol. 2011;1:1–7.
Miyazawa T. Endogenous retroviruses as potential hazards for vaccines. Biologicals. 2011;38:371–6.
Eddy B, Borman G, Berkeley W, Young R. Tumors induced in hamsters by injection of rhesus monkey kidney cell extracts. Proc Soc Exp Biol Med. 1961;107:191–7.
Butel JS, Lednicky JA. Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst. 1999;91:119–34.
Carbone M, Rizzo P, Pass HI. Simian virus 40, polio vaccines and human tumors: a review of recent developments. Oncogene. 1997;15:1877–88.
Strickler HD, Rosenberg PS, Devesa SS, et al. Contamination of poliovirus vaccines with simian virus 40 (1955–1963) and subsequent cancer rates. JAMA. 1998;279:292–5.
Olin P, Giesecke J. Potential exposure to SV40 in polio vaccines used in Sweden during 1957: no impact on cancer incidence rates 1960 to 1993. Dev Biol Stand. 1998;94:227–33.
Carroll-Pankhurst C, Engles EA, Strickler HD, et al. Thirty-five year mortality following receipt of SV40-contaminated polio virus vaccine during the neonatal period. Br J Cancer. 2001;85:1295–7.
Engels EA, Rodman LH, Frisch M, et al. Childhood exposure to simian virus 40-contaminated poliovirus vaccine and risk of AIDS-associated non-Hodgkin’s lymphoma. Int J Cancer. 2003;106:283–7.
Rollison DE, Page WF, Crawford H, et al. Case–control study of cancer among US Army veterans exposed to simian virus 40-contaminated adenovirus vaccine. Am J Epidemiol. 2004;160:317–24.
National Research Council. Immunization safety review: SV40 contamination of polio vaccine and cancer. Washington, DC: The National Academies Press; 2002.
Poulin DL, DeCaprio JA. Is there a role for SV40 in human cancer. J Clin Oncol. 2006;24:4356–65.
Lopez-Rios F, Illei PB, Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet. 2004;364:1157–66.
Silverman RH, Nguyen C, Weight CJ, Klein EA. The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. Nat Rev Urol. 2010;7:392–402.
Paprotka T, Delviks-Frankenberry KA, Cingoz O, et al. Recombinant origin of the retrovirus XMRV. Science. 2011. www.scienceexpress.org/31May2001/page1/10.1126/science.1205292
Switzer WM, Zheng H, Simmons G, et al. No evidence of murine leukemia virus-related viruses in live attenuated human vaccines. PLoS One. 2011;6:e29223.